Parnax Lab [PARNAXLAB] vs Sun Pharma Advanced [SPARC] Detailed Stock Comparison
Parnax Lab
BSE
Loading...
Sun Pharma Advanced
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Parnax Lab wins in 11 metrics, Sun Pharma Advanced wins in 7 metrics, with 0 ties. Parnax Lab appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Parnax Lab | Sun Pharma Advanced | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 12.99 | -13.85 | Sun Pharma Advanced |
| Price-to-Book Ratio | 1.69 | -21.83 | Sun Pharma Advanced |
| Debt-to-Equity Ratio | 83.52 | -1.24 | Sun Pharma Advanced |
| PEG Ratio | -0.73 | 0.30 | Parnax Lab |
| EV/EBITDA | 8.04 | -17.66 | Sun Pharma Advanced |
| Profit Margin (TTM) | 5.67% | -53.22% | Parnax Lab |
| Operating Margin (TTM) | 10.29% | -568.05% | Parnax Lab |
| EBITDA Margin (TTM) | 10.29% | N/A | N/A |
| Return on Equity | 13.84% | 157.88% | Sun Pharma Advanced |
| Return on Assets (TTM) | 6.07% | -102.08% | Parnax Lab |
| Free Cash Flow (TTM) | $137.24M | $-3.71B | Parnax Lab |
| 1-Year Return | 10.65% | -35.58% | Parnax Lab |
| Price-to-Sales Ratio (TTM) | 0.74 | 73.39 | Parnax Lab |
| Enterprise Value | $2.07B | $50.08B | Sun Pharma Advanced |
| EV/Revenue Ratio | 1.09 | 77.52 | Parnax Lab |
| Gross Profit Margin (TTM) | 43.83% | -10.68% | Parnax Lab |
| Revenue per Share (TTM) | $166 | $2 | Parnax Lab |
| Earnings per Share (Diluted) | $9.43 | $-9.19 | Parnax Lab |
| Beta (Stock Volatility) | 0.46 | 0.31 | Sun Pharma Advanced |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Parnax Lab vs Sun Pharma Advanced Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Parnax Lab | 4.48% | 6.15% | 9.38% | 43.81% | 42.55% | -21.14% |
| Sun Pharma Advanced | -1.47% | -3.03% | -4.92% | -13.36% | 17.11% | -28.95% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Parnax Lab | 10.65% | 44.25% | 647.19% | 397.20% | 828.12% | 1,483.33% |
| Sun Pharma Advanced | -35.58% | -37.00% | -18.78% | -60.87% | 53.70% | -50.94% |
Performance & Financial Health Analysis: Parnax Lab vs Sun Pharma Advanced
| Metric | PARNAXLAB | SPARC |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.41B | ₹47.41B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 5,491 | 250,949 |
| 90 Day Avg. Volume | 6,550 | 349,451 |
| Last Close | ₹133.00 | ₹142.59 |
| 52 Week Range | ₹81.00 - ₹193.50 | ₹109.30 - ₹241.00 |
| % from 52W High | -31.27% | -40.83% |
| All-Time High | ₹193.50 (Nov 04, 2024) | ₹875.00 (Apr 24, 2006) |
| % from All-Time High | -31.27% | -83.70% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.07% | -0.43% |
| Quarterly Earnings Growth | -0.18% | -0.43% |
| Financial Health | ||
| Profit Margin (TTM) | 0.06% | -0.53% |
| Operating Margin (TTM) | 0.10% | -5.68% |
| Return on Equity (TTM) | 0.14% | 1.58% |
| Debt to Equity (MRQ) | 83.52 | -1.24 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹72.57 | ₹-6.69 |
| Cash per Share (MRQ) | ₹2.34 | ₹0.06 |
| Operating Cash Flow (TTM) | ₹297.41M | ₹-3,484,287,000 |
| Levered Free Cash Flow (TTM) | ₹115.19M | ₹-3,425,094,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Parnax Lab vs Sun Pharma Advanced
| Metric | PARNAXLAB | SPARC |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 12.99 | -13.85 |
| Forward P/E | N/A | 2.64 |
| PEG Ratio | -0.73 | 0.30 |
| Price to Sales (TTM) | 0.74 | 73.39 |
| Price to Book (MRQ) | 1.69 | -21.83 |
| Market Capitalization | ||
| Market Capitalization | ₹1.41B | ₹47.41B |
| Enterprise Value | ₹2.07B | ₹50.08B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.09 | 77.52 |
| Enterprise to EBITDA | 8.04 | -17.66 |
| Risk & Other Metrics | ||
| Beta | 0.46 | 0.31 |
| Book Value per Share (MRQ) | ₹72.57 | ₹-6.69 |
Financial Statements Comparison: Parnax Lab vs Sun Pharma Advanced
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PARNAXLAB | SPARC |
|---|---|---|
| Revenue/Sales | ₹533.76M | ₹96.40M |
| Cost of Goods Sold | ₹299.82M | ₹106.70M |
| Gross Profit | ₹233.94M | ₹-10.30M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹54.94M | ₹-547.60M |
| EBITDA | ₹76.21M | ₹-429.40M |
| Pre-Tax Income | ₹44.55M | ₹-518.10M |
| Income Tax | ₹11.80M | ₹600,000 |
| Net Income (Profit) | ₹32.75M | ₹-518.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PARNAXLAB | SPARC |
|---|---|---|
| Cash & Equivalents | ₹5.50M | ₹19.64M |
| Total Current Assets | ₹683.40M | ₹261.97M |
| Total Current Liabilities | ₹743.34M | ₹3.74B |
| Long-Term Debt | ₹262.42M | ₹1.07B |
| Total Shareholders Equity | ₹832.42M | ₹-2.17B |
| Retained Earnings | N/A | ₹-23.22B |
| Property, Plant & Equipment | ₹1.09B | ₹178.02M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PARNAXLAB | SPARC |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PARNAXLAB | SPARC |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 5,491 | 250,949 |
| Average Daily Volume (90 Day) | 6,550 | 349,451 |
| Shares Outstanding | 11.49M | 324.52M |
| Float Shares | 2.99M | 91.74M |
| % Held by Insiders | 0.74% | 0.73% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Parnax Lab vs Sun Pharma Advanced
| Metric | PARNAXLAB | SPARC |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |